Vancomycin + Daptomycin + Semi-Synthetic Penicillin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Complicated Skin and Skin Structure Infections
Conditions
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
Trial Timeline
Apr 19, 2010 → Jun 12, 2012
NCT ID
NCT01104662About Vancomycin + Daptomycin + Semi-Synthetic Penicillin
Vancomycin + Daptomycin + Semi-Synthetic Penicillin is a approved stage product being developed by Merck for Complicated Skin and Skin Structure Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT01104662. Target conditions include Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment.
What happened to similar drugs?
3 of 20 similar drugs in Complicated Skin and Skin Structure Infections were approved
Approved (3) Terminated (2) Active (16)
🔄HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01104662 | Approved | Terminated |
Competing Products
20 competing products in Complicated Skin and Skin Structure Infections